Junchang Cui

1.4k total citations
34 papers, 1.0k citations indexed

About

Junchang Cui is a scholar working on Molecular Medicine, Pharmacology and Epidemiology. According to data from OpenAlex, Junchang Cui has authored 34 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Medicine, 22 papers in Pharmacology and 14 papers in Epidemiology. Recurrent topics in Junchang Cui's work include Antibiotic Resistance in Bacteria (24 papers), Antibiotics Pharmacokinetics and Efficacy (22 papers) and Pneumonia and Respiratory Infections (10 papers). Junchang Cui is often cited by papers focused on Antibiotic Resistance in Bacteria (24 papers), Antibiotics Pharmacokinetics and Efficacy (22 papers) and Pneumonia and Respiratory Infections (10 papers). Junchang Cui collaborates with scholars based in China, Philippines and United States. Junchang Cui's co-authors include Wentao Ni, You-ning Liu, Chuanqi Wei, Jin Zhao, Rui Wang, Yuliang Han, Rui Wang, Karl Drlica, Rui Wang and Xilin Zhao and has published in prestigious journals such as PLoS ONE, Scientific Reports and The Journal of Infectious Diseases.

In The Last Decade

Junchang Cui

32 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Junchang Cui China	18	653	429	277	200	154	34	1.0k
Lisa Liolios Australia	8	627 1.0×	267 0.6×	334 1.2×	180 0.9×	164 1.1×	12	930
Neang S. Ly United States	15	753 1.2×	538 1.3×	273 1.0×	83 0.4×	203 1.3×	24	1.0k
Antonios Markogiannakis Greece	11	565 0.9×	210 0.5×	176 0.6×	215 1.1×	125 0.8×	20	737
Georgios Meletis Greece	14	812 1.2×	248 0.6×	157 0.6×	287 1.4×	219 1.4×	58	1.1k
Sofia K. Kasiakou Greece	14	888 1.4×	645 1.5×	560 2.0×	119 0.6×	158 1.0×	16	1.4k
Cesira Giordano Italy	14	698 1.1×	324 0.8×	229 0.8×	145 0.7×	90 0.6×	29	999
Noriel Mariano United States	19	780 1.2×	440 1.0×	401 1.4×	209 1.0×	148 1.0×	31	1.1k
Michael A. Zhanel Canada	9	610 0.9×	389 0.9×	275 1.0×	83 0.4×	146 0.9×	10	877
Laura J. Rojas United States	16	746 1.1×	301 0.7×	189 0.7×	213 1.1×	162 1.1×	48	893
Maristela Pinheiro Freire Brazil	23	545 0.8×	263 0.6×	511 1.8×	156 0.8×	82 0.5×	71	1.3k

Countries citing papers authored by Junchang Cui

Since Specialization

Citations

This map shows the geographic impact of Junchang Cui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junchang Cui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junchang Cui more than expected).

Fields of papers citing papers by Junchang Cui

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junchang Cui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junchang Cui. The network helps show where Junchang Cui may publish in the future.

Co-authorship network of co-authors of Junchang Cui

This figure shows the co-authorship network connecting the top 25 collaborators of Junchang Cui. A scholar is included among the top collaborators of Junchang Cui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Junchang Cui. Junchang Cui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cui, Junchang, et al.. (2025). The Role of blaOXA-101 and blaOXA-573 in Extensively Drug-Resistant/ Pan Drug-Resistant (XDR/PDR) Pseudomonas aeruginosa Resistance to Ceftazidime-Avibactam. Infection and Drug Resistance. Volume 18. 2547–2555.

Kang, Yixin, Zihan Zhang, & Junchang Cui. (2025). Clinical risk factors, antimicrobial therapy, and virulence-associated mortality in patients with extensively drug-resistant or pan-drug-resistant (XDR/PDR) Pseudomonas aeruginosa pulmonary infections. International Journal of Infectious Diseases. 162. 108198–108198.

Zhang, Xinxin, Chenglong Li, Junchang Cui, et al.. (2025). Clinical Outcomes of Hospitalized Immunocompromised Patients With COVID-19 and the Impact of Hyperinflammation: A Retrospective Cohort Study. Journal of Inflammation Research. Volume 18. 3385–3397. 1 indexed citations

Wu, Jie, et al.. (2023). In vitro Antimicrobial Activity and Dose Optimization of Eravacycline and Other Tetracycline Derivatives Against Levofloxacin-Non-Susceptible and/or Trimethoprim-Sulfamethoxazole-Resistant Stenotrophomonas maltophilia. Infection and Drug Resistance. Volume 16. 6005–6015. 5 indexed citations

Yang, Jiyong, et al.. (2023). Optimal treatment of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections or lower respiratory tract infections caused by extensively drug-resistant or pan drug-resistant (XDR/PDR) Pseudomonas aeruginosa. Frontiers in Cellular and Infection Microbiology. 13. 1023948–1023948. 11 indexed citations

Yang, Zhen, et al.. (2017). Pharmacodynamics of tigecycline alone and in combination with colistin against clinical isolates of multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model. International Journal of Antimicrobial Agents. 49(5). 609–616. 26 indexed citations

Ni, Wentao, Yuliang Han, Jin Zhao, et al.. (2016). Serum soluble urokinase-type plasminogen activator receptor as a biological marker of bacterial infection in adults: a systematic review and meta-analysis. Scientific Reports. 6(1). 39481–39481. 45 indexed citations

Wei, Chuanqi, et al.. (2016). Evaluation of Trimethoprim/Sulfamethoxazole (SXT), Minocycline, Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for SXT-Susceptible and SXT-Resistant Stenotrophomonas maltophilia by In Vitro Time-Kill Experiments. PLoS ONE. 11(3). e0152132–e0152132. 68 indexed citations

Ni, Wentao, Yuliang Han, Chuanqi Wei, et al.. (2016). Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections. Medicine. 95(11). e3126–e3126. 88 indexed citations

10.

Ni, Wentao, Chuanqi Wei, Beibei Liang, et al.. (2016). Tigecycline-Amikacin Combination Effectively Suppresses the Selection of Resistance in Clinical Isolates of KPC-Producing Klebsiella pneumoniae. Frontiers in Microbiology. 7. 1304–1304. 19 indexed citations

11.

Ni, Wentao, Yuliang Han, Jin Zhao, et al.. (2015). Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis. International Journal of Antimicrobial Agents. 47(2). 107–116. 77 indexed citations

12.

Ni, Wentao, et al.. (2015). Efficacy of polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. The Brazilian Journal of Infectious Diseases. 19(2). 170–180. 32 indexed citations

13.

Ni, Wentao, et al.. (2015). Prophylactic Use of Macrolide Antibiotics for the Prevention of Chronic Obstructive Pulmonary Disease Exacerbation: A Meta-Analysis. PLoS ONE. 10(3). e0121257–e0121257. 77 indexed citations

14.

Ni, Wentao, et al.. (2014). In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: A systematic review and meta-analysis. International Journal of Antimicrobial Agents. 45(1). 8–18. 100 indexed citations

15.

Ni, Wentao, et al.. (2014). Effect of Proton Pump Inhibitors on In Vitro Activity of Tigecycline against Several Common Clinical Pathogens. PLoS ONE. 9(1). e86715–e86715. 16 indexed citations

16.

Ni, Wentao, Junchang Cui, Beibei Liang, et al.. (2013). In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii. The Journal of Antibiotics. 66(12). 705–708. 38 indexed citations

17.

Ni, Wentao, et al.. (2013). Disseminated cryptococcosis initially presenting as cellulitis in a patient suffering from nephrotic syndrome. BMC Nephrology. 14(1). 20–20. 21 indexed citations

18.

Ni, Wentao, Xi Song, & Junchang Cui. (2013). Testing the mutant selection window hypothesis with Escherichia coli exposed to levofloxacin in a rabbit tissue cage infection model. European Journal of Clinical Microbiology & Infectious Diseases. 33(3). 385–389. 16 indexed citations

19.

Yuan, Xin, Beibei Liang, Rui Wang, et al.. (2012). Treatment of community-acquired pneumonia with moxifloxacin: a meta-analysis of randomized controlled trials. Journal of Chemotherapy. 24(5). 257–267. 10 indexed citations

20.

Cui, Junchang, You-ning Liu, & Liangan Chen. (2009). Mutant prevention concentration of tigecycline for carbapenem-susceptible and -resistant Acinetobacter baumannii. The Journal of Antibiotics. 63(1). 29–31. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact